MOXGUARD
MOXGUARD delivers intracameral moxifloxacin 0.5% at cataract case-close — linked to a 4-fold drop in postoperative endophthalmitis in real-world data, independent of patient compliance.
See MOXGUARD up close.
Designed with clear labelling and surgeon-ready packaging for fast, confident identification in the operating theatre.
How MOXGUARD works
inside the anterior chamber.
Moxifloxacin targets bacterial DNA gyrase and topoisomerase IV, disrupting replication across both gram-positive and gram-negative organisms.
Intracameral Injection
MOXGUARD is injected directly into the anterior chamber at the conclusion of cataract surgery, achieving immediate high drug concentration at the surgical site.
Dual-Target Inhibition
Moxifloxacin simultaneously inhibits bacterial DNA gyrase and topoisomerase IV — two essential enzymes for bacterial DNA replication and repair.
Broad-Spectrum Coverage
Effective against common endophthalmitis pathogens including Staphylococcus, Streptococcus, and gram-negative organisms frequently encountered post-operatively.
Concentration-Dependent Activity
Delivers bactericidal concentrations well above MIC levels directly where they are needed — reducing dependence on patient topical compliance post-surgery.
Technical profile.
Formulated and packaged for direct integration into cataract surgery workflows.
Active Ingredient
Class
Preservative
Route
Volume
Packaging
Why surgeons trust
intracameral prophylaxis.
MOXGUARD addresses the critical need for reliable endophthalmitis prophylaxis — directly at the point of greatest vulnerability.
Endophthalmitis Prophylaxis
Intracameral antibiotic administration at the end of cataract surgery is increasingly recognized as an important step in reducing post-operative endophthalmitis risk.
ProphylacticCompliance Independent
Administered by the surgeon intraoperatively — removes the variable of patient adherence to topical antibiotic regimens during the critical early post-operative period.
Surgeon-ControlledReady-to-Use Format
Eliminates the need for pharmacy compounding — reducing the risk of dilution errors and contamination associated with preparation from topical formulations.
No CompoundingOptimized for Cataract Surgery
Designed specifically for the cataract surgical workflow — appropriate concentration, volume, and packaging for seamless integration into operative protocols.
OT-ReadyThe case for intracameral prophylaxis.
Intracameral moxifloxacin as an endophthalmitis-prophylaxis class is supported by independent, peer-reviewed research — not manufacturer-sponsored claims. A selection of the published evidence:
4-fold reduction in postoperative endophthalmitis
Haripriya A, et al. Aravind Eye Hospital, 116,714 eyes (Feb 2014–Apr 2015): endophthalmitis fell from 0.08% (pre-prophylaxis) to 0.02% with routine intracameral moxifloxacin. Ophthalmology, 2016.
PubMed 26522705Confirmed in real-world Indian tertiary care
Prophylactic intracameral moxifloxacin significantly reduced post-cataract-surgery endophthalmitis at a rural Indian tertiary eye care facility.
PubMed 33821388Guideline-endorsed standard of care
The AAO Cataract Preferred Practice Pattern (2022) and ESCRS guidelines (2013) both recognize strong evidence supporting intracameral antibiotic injection as endophthalmitis prophylaxis at cataract surgery closure.
Cited studies evaluate intracameral moxifloxacin as a drug class for endophthalmitis prophylaxis and are independent of Agaaz Ophthalmics. MOXGUARD delivers moxifloxacin 0.5% via the same intracameral route studied in this literature.
Where MOXGUARD fits
Integrated at the conclusion of cataract surgery — a single, controlled step before wound closure.
Incision & Access
Clear corneal incision and anterior chamber entry
Capsulorhexis
Anterior capsule opening with staining
Phacoemulsification
Cataractous lens removal and aspiration
IOL Implantation
Lens insertion into capsular bag
MOXGUARD
Intracameral moxifloxacin prophylaxis
Wound Closure
Hydration of incision and completion
Designed for the operating theatre.
Single-Dose Presentation
Individually packaged and sterilized for single-patient use to reduce cross-contamination risk.
Preservative-Free Formulation
No added preservatives — critical for intracameral administration where preservative-related toxicity is a concern.
Clear Labeling
Concentration and expiry prominently visible — supporting safe identification in fast-paced OT environments.
Storage Conditions
Store below 25°C, protected from light. No refrigeration required — practical for a range of storage and logistics conditions.
Interested in MOXGUARD?
Contact Agaaz Ophthalmics for detailed product information, regulatory documentation, or distribution enquiries.
